Logo image of PLSE

PULSE BIOSCIENCES INC (PLSE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PLSE - US74587B1017 - Common Stock

15.26 USD
+0.88 (+6.12%)
Last: 12/19/2025, 8:10:18 PM
15.26 USD
0 (0%)
After Hours: 12/19/2025, 8:10:18 PM
Fundamental Rating

2

Taking everything into account, PLSE scores 2 out of 10 in our fundamental rating. PLSE was compared to 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for PLSE as it has an excellent financial health rating, but there are worries on the profitability. PLSE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

PLSE had negative earnings in the past year.
PLSE had a negative operating cash flow in the past year.
PLSE had negative earnings in each of the past 5 years.
In the past 5 years PLSE always reported negative operating cash flow.
PLSE Yearly Net Income VS EBIT VS OCF VS FCFPLSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of PLSE (-68.71%) is worse than 72.73% of its industry peers.
PLSE has a Return On Equity (-80.62%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -68.71%
ROE -80.62%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLSE Yearly ROA, ROE, ROICPLSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

PLSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLSE Yearly Profit, Operating, Gross MarginsPLSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

8

2. Health

2.1 Basic Checks

The number of shares outstanding for PLSE has been increased compared to 1 year ago.
PLSE has more shares outstanding than it did 5 years ago.
PLSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLSE Yearly Shares OutstandingPLSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLSE Yearly Total Debt VS Total AssetsPLSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 29.27 indicates that PLSE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 29.27, PLSE belongs to the top of the industry, outperforming 97.86% of the companies in the same industry.
There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.27
ROIC/WACCN/A
WACCN/A
PLSE Yearly LT Debt VS Equity VS FCFPLSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 10.02 indicates that PLSE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.02, PLSE belongs to the top of the industry, outperforming 93.05% of the companies in the same industry.
A Quick Ratio of 10.01 indicates that PLSE has no problem at all paying its short term obligations.
PLSE's Quick ratio of 10.01 is amongst the best of the industry. PLSE outperforms 93.58% of its industry peers.
Industry RankSector Rank
Current Ratio 10.02
Quick Ratio 10.01
PLSE Yearly Current Assets VS Current LiabilitesPLSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

0

3. Growth

3.1 Past

PLSE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.68%.
EPS 1Y (TTM)-40.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-81.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -35.81% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.67%
EPS Next 2Y-35.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLSE Yearly Revenue VS EstimatesPLSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2025 2026 1M 2M 3M
PLSE Yearly EPS VS EstimatesPLSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PLSE. In the last year negative earnings were reported.
Also next year PLSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLSE Price Earnings VS Forward Price EarningsPLSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLSE Per share dataPLSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as PLSE's earnings are expected to decrease with -35.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.81%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for PLSE!.
Industry RankSector Rank
Dividend Yield 0%

PULSE BIOSCIENCES INC

NASDAQ:PLSE (12/19/2025, 8:10:18 PM)

After market: 15.26 0 (0%)

15.26

+0.88 (+6.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-25 2026-03-25
Inst Owners8.92%
Inst Owner Change-1.3%
Ins Owners72.64%
Ins Owner Change0.38%
Market Cap1.03B
Revenue(TTM)86.00K
Net Income(TTM)-74.73M
Analysts85.71
Price Target22.44 (47.05%)
Short Float %13.96%
Short Ratio15.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.44%
Min EPS beat(2)8.29%
Max EPS beat(2)24.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)2.56%
EPS NY rev (3m)2.56%
Revenue NQ rev (1m)-66.67%
Revenue NQ rev (3m)-66.67%
Revenue NY rev (1m)-72.8%
Revenue NY rev (3m)-72.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12025.23
P/FCF N/A
P/OCF N/A
P/B 11.16
P/tB 11.6
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS1.37
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.71%
ROE -80.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.75%
Cap/Sales 329.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.02
Quick Ratio 10.01
Altman-Z 29.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.68%
Cap/Depr(5y)25.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-81.25%
EPS Next Y-26.67%
EPS Next 2Y-35.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.76%
OCF growth 3YN/A
OCF growth 5YN/A

PULSE BIOSCIENCES INC / PLSE FAQ

What is the fundamental rating for PLSE stock?

ChartMill assigns a fundamental rating of 2 / 10 to PLSE.


What is the valuation status of PULSE BIOSCIENCES INC (PLSE) stock?

ChartMill assigns a valuation rating of 0 / 10 to PULSE BIOSCIENCES INC (PLSE). This can be considered as Overvalued.


Can you provide the profitability details for PULSE BIOSCIENCES INC?

PULSE BIOSCIENCES INC (PLSE) has a profitability rating of 0 / 10.